|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
It argues against ZnT8 autoimmunity arising from molecular mimicry and suggests a mechanistic link between the two major forms of diabetes.
|
18591387 |
2008 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we characterize an emerging role of ZnT-8 in diabetes and discuss potential mechanisms of its involvement in the etiology of both forms of diabetes.
|
19655390 |
2009 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SLC30A8 genotype strongly influenced ZnT8A type and diabetes risk in ZnT8A-COOH-positive children.
|
19590848 |
2009 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8 was therefore proposed as a therapeutic target for diabetes, and recent genome-wide association studies identified polymorphisms in the ZNT8 gene conferring increased type 2 diabetes risk.
|
19095428 |
2009 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, variants near insulin-like growth factor-binding protein 2 (IGFBP2), CDK5 regulatory subunit associated protein 1-like 1 (CDKAL1), solute carreir family 30 (zinc transporter), member 8 (SLC30A8), hematopoietically-expressed homeobox (HHEX), and transcription factor 7-like2 (TCF7L2) were clearly associated with diabetes; no evidence for an association to CAC was observable.
|
20616309 |
2010 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of GADAs, IA-2As, and ZnT8As in combination allowed a stratification of clinical phenotype, with younger age of onset of diabetes and characteristics of more severe insulin deficiency (higher fasting glucose and A1C, lower BMI, total cholesterol, and triglycerides) in patients with all three markers, with progressive attenuation in patients with two, one, and no antibodies (all P(trend) < 0.001).
|
19808923 |
2010 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-TripleA was detected in 1678 (65%) patients with T1D, 4 (9%) T2D, 3 (11%) MODY and in none (0%) of the patients with secondary diabetes.
|
21708156 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoantibody-negative patients were retested at median diabetes duration of 3.2 yr (range 0.9-16.2) for autoantibodies (GAD, IA2, ZnT8), human leukocyte antigen (HLA) typing, non-fasting C-peptide, and sequencing of HNF4A, HNF1A, KCNJ11, and INS.
|
21518407 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blood samples were obtained from 900 patients with age from 1 month to 25 years (median age 11.1 years) within 2 weeks of diabetes onset to test anti-islet autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma antigen (IA-2AA), the zinc transporter-8 (ZnT8AA), and islet-cell antibodies (ICA).
|
21138544 |
2011 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic and physiological studies suggest a role for the zinc transporter gene SLC30A8 in diabetes risk, possibly through effects on insulin-processing in beta cells.
|
21779873 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Worldwide researchers have invested time, effort, and money during the last years to find new genes associated with diabetes susceptibility, such as LOC387761, HHEX, EXT2, and SLC30A8.
|
21198374 |
2011 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes.
|
21099260 |
2011 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We searched all the publications about the association between SLC30A8 and diabetes from PubMed, and evaluated the association between SLC30A8 rs13266634 C/T polymorphism and T2DM, IGT and T1DM, respectively, by meta-analysis of all the validated studies.
|
21131091 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rate of progression from NFG to IFG was significantly greater in participants carrying the risk allele at MTNR1B (p = 1 × 10(-4)), nominally greater at GCK and SLC30A8 (p < 0.05) and nominally smaller at IGF2BP2 (p = 0.01) than the rate of progression from IFG to diabetes by the LRT.
|
22038522 |
2012 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of ZnT8A were measured in 2,239 British type 1 diabetic individuals diagnosed before age 17 years, with a median duration of diabetes of 4 years.
|
22526605 |
2012 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Diabetes Autoimmunity Study in the Young (DAISY) followed prospectively for development of persistent IA (autoantibodies to insulin, GAD65, IA-2, or ZnT8 on at least two consecutive exams) and diabetes 1715 non-Hispanic white children at increased genetic risk for T1D.
|
22776074 |
2012 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
None of type 2 diabetes risk alleles at the CDKAL1, CDKN2A/2B, FTO, HHEX-IDE, HMGA2, IGF2BP2, KCNJ11, KCNQ1, MTNR1B, PPARG and SLC30A8 loci were associated with the development of islet autoantibodies or diabetes.
|
22558147 |
2012 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed diabetes risk associated with zinc transporter-8 antibodies (ZnT8A), islet cell antibodies (ICA), and HLA type and age in relatives of people with type 1 diabetes with the standard biochemical autoantibodies (BAA) to insulin (IAA), GAD65 (GAD65A), and/or insulinoma-associated protein 2 antigen (IA-2A).
|
22446173 |
2012 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Associations between ZnT8 antibody (ZnT8A), phenotype and the genetic variant rs13266634 in the SLC30A8 gene have primarily been studied in patients with young-onset diabetes.
|
23061550 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A registry-based group of 288 persistently autoantibody-positive (Ab(+)) offspring/siblings (aged 0-39 years) of known patients (Ab(+) against insulin, GAD, IA-2 and/or ZnT8) were typed for HLA-DQ, -A and -B and monitored from the first Ab(+) sample for development of diabetes within 5 years.
|
23712485 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
STZ treatment also suppressed expression of a wide range of genes linked with key β-cell functions or diabetes development, such as G6pc2, Slc2a2 (Glut2), Slc30a8, Neurod1, Ucn3, Gad1, Isl1, Foxa2, Vdr, Pdx1, Fkbp1b and Abcc8, suggesting global β-cell defects in STZ-treated islets.
|
23828045 |
2013 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A rare variant association study has now established the direction of effect, surprisingly showing that loss-of-function mutations in SLC30A8 are protective against diabetes.
|
24675520 |
2014 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DESIGN/OUTCOME: We sequenced exons in SLC30A8 in 380 Diabetes Prevention Program (DPP) participants and identified 44 novel variants, which were genotyped in 3445 DPP participants and tested for association with diabetes incidence and measures of insulin secretion and processing.
|
24471563 |
2014 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The dependence on ZnT8 of hypoxia-induced changes in cell survival may contribute to the actions of SLC30A8 variants on diabetes risk in humans.
|
24865615 |
2014 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we examined the association between variants in fat mass- and obesity-associated [rs9939609 (A/T)], melanocortin 4 receptor [rs17782313 (C/T), and rs12970134 (A/G)], SLC30A8 [rs13266634 (C/T)], and a member of the potassium voltage-gated channels [rs2237892(C/T)] genes in diabetes patients from Saudi Arabia.
|
25501231 |
2014 |